牛牛AI助手已提取核心信息
180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. The reverse stock split was approved by the company's Board of Directors following authorization from the company's stockholders to amend the Second Amended and Restated Certificate of Incorporation. This move aims to comply with the Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. Prior to the split, the company's common stock was trading below the Nasdaq's minimum $1.00 requirement. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to approximately 0.6 million. No fractional shares will be issued; stockholders who would have received a...Show More
180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. The reverse stock split was approved by the company's Board of Directors following authorization from the company's stockholders to amend the Second Amended and Restated Certificate of Incorporation. This move aims to comply with the Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. Prior to the split, the company's common stock was trading below the Nasdaq's minimum $1.00 requirement. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to approximately 0.6 million. No fractional shares will be issued; stockholders who would have received a fractional share will receive one whole share instead. The company's common stock will continue to trade on Nasdaq under the symbol 'ATNF'. In related news, the company has also reported the exercise of pre-funded warrants resulting in the issuance of 1,111,878 shares of common stock. Additionally, a judge has granted a Motion for Partial Summary Judgment in favor of 180 Life Sciences in a lawsuit involving the company's insurance carriers, which may lead to the advancement of defense costs related to SEC subpoenas.
180 生命科学公司宣布对普通股进行1比19的反向分割，自美国东部时间2024年2月28日凌晨 12:01 起生效。在公司股东授权修改第二经修订和重述的公司注册证书后，公司董事会批准了反向股票拆分。此举旨在遵守纳斯达克继续在纳斯达克资本市场上市的最低出价要求。拆分之前，该公司的普通股交易价格低于纳斯达克最低1.00美元的要求。反向股票拆分将使已发行股票的数量从约1130万股减少到约60万股。不会发行零碎股票；本来可以获得部分股份的股东将获得整股。该公司的普通股将继续在纳斯达克上市，股票代码为 “ATNF”。在相关新闻中，该公司还报告了行使预先注资的认股权证，导致发行了1,111,878股普通股。此外，在涉及180生命科学公司的诉讼中，法官批准了部分即决判决的动议，该动议可能导致与美国证券交易委员会传票相关的辩护费用增加。
180 生命科学公司宣布对普通股进行1比19的反向分割，自美国东部时间2024年2月28日凌晨 12:01 起生效。在公司股东授权修改第二经修订和重述的公司注册证书后，公司董事会批准了反向股票拆分。此举旨在遵守纳斯达克继续在纳斯达克资本市场上市的最低出价要求。拆分之前，该公司的普通股交易价格低于纳斯达克最低1.00美元的要求。反向股票拆分将使已发行股票的数量从约1130万股减少到约60万股。不会发行零碎股票；本来可以获得部分股份的股东将获得整股。该公司的普通股将继续在纳斯达克上市，股票代码为 “ATNF”。在相关新闻中，该公司还报告了行使预先注资的认股权证，导致发行了1,111,878股普通股。此外，在涉及180生命科学公司的诉讼中，法官批准了部分即决判决的动议，该动议可能导致与美国证券交易委员会传票相关的辩护费用增加。
有用
没用